Anika Therapeutics, Inc. (ANIK)
Valuation Overview•Is Anika Therapeutics, Inc. Overvalued or Undervalued?
Popular:
Average quality — mixed signals, monitor closely
Returns capital via buybacks — no dividend
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $-0.07 | $0.27 | +485.7% | ||
| Q1'26 | $-0.13 | $0.31 | +348.0% | ||
| Q4'25 | $0.02 | $0.04 | +100.0% | ||
| Q3'25 | $-0.13 | $-0.13 | +0.0% | ||
| Q2'25 | $0.09 | $-0.06 | -166.7% | ||
| Q1'25 | $-0.01 | $-0.03 | -200.0% | ||
| Q4'24 | $0.30 | $-0.25 | -183.3% | ||
| Q3'24 | $0.23 | $0.17 | -26.1% |
Total return, benchmark alpha, and annual history in one section.
3Y, 5Y, and 10Y use CAGR when available.
| Period | Return | vs S&P | Dividends |
|---|---|---|---|
| YTD | +61.7% | +54.3% | — |
| 1Y | +7.4% | -23.9% | — |
| 3YCAGR | -16.5% | -37.9% | — |
| 5YCAGR | -18.0% | -30.3% | — |
| 10YCAGR | -10.1% | -23.8% | — |
Year-by-year total return versus SPY, including dividend contribution.
| Year | Stock Return | SPY Return | Alpha | Dividends |
|---|---|---|---|---|
| 2026YTDBest | +53.6% | +0.4% | +53.2% | — |
| 2025Worst | -40.7% | +16.6% | -57.4% | — |
| 2024 | -27.4% | +24.0% | -51.4% | — |
| 2023 | -23.1% | +24.8% | -47.9% | — |
| 2022 | -19.0% | -19.9% | +1.0% | — |
| 2021 | -16.4% | +28.8% | -45.2% | — |
| 2020 | -13.6% | +15.1% | -28.7% | — |
| 2019 | +50.2% | +28.7% | +21.6% | — |
Based on our multi-model analysis of Anika Therapeutics, Inc. (ANIK) at $15.12: Relative valuation verdict: Significantly Undervalued vs industry peers. Fundamental quality score: 48/100 (moderate). Wall Street consensus: Buy from 6 analysts. This is a quantitative summary combining DCF intrinsic value, peer-based relative valuation, quality scoring, and analyst consensus — not a buy/sell recommendation. Always consult a qualified financial advisor before investing.
Anika Therapeutics, Inc. has multiple fair value estimates from different frameworks: Relative fair value: $31.85 (Significantly Undervalued, +211.3% vs current price). We recommend comparing all three lenses — when DCF, relative, and analyst targets converge, the signal is stronger. When they diverge, investigate what assumptions differ.
Anika Therapeutics, Inc.'s financial health as measured by our composite scoring: Overall quality score: 48/100. Piotroski F-Score: 6/9 (moderate). Altman Z-Score: 3.8 (safe zone — low bankruptcy risk). Return on invested capital: -7.1%. Cash conversion (OCF/NI): -1.03x (earnings exceed cash generation). The quality score blends profitability (ROIC, ROE, margins), solvency (leverage, coverage, Z-Score), and growth trajectory into a single 0–100 framework updated end-of-day.
Anika Therapeutics, Inc.'s performance profile: 1-year total return: +7.4%. 1-year alpha vs S&P 500: -23.9% (underperforming the benchmark). 5-year CAGR: -18.0%. Maximum drawdown (1Y): -45.5%. Relative Strength rating: 85/99 (strong momentum). Beta: 1.14 (similar volatility to the market). Total returns include reinvested dividends. Alpha is calculated against the S&P 500 Total Return Index over matching periods.
Anika Therapeutics, Inc. does not currently pay a dividend. The company returns capital to shareholders via share buybacks, with a buyback yield of 4.7% and a 1-year share count change of -2.6%. Total shareholder yield (including buybacks): 4.7%.
Wall Street's outlook on Anika Therapeutics, Inc.: Consensus rating: Buy from 6 covering analysts. Earnings beat rate: 33% with a 3-quarter consecutive beat streak. Analyst estimates are blended into our proprietary model with weight based on coverage depth and historical accuracy. We track estimate revisions, beat rates, and grade changes daily.
Key risks identified for Anika Therapeutics, Inc.: Drawdown risk: The stock experienced a -45.5% max drawdown in the past year. Note: This model does not capture regulatory changes, management decisions, competitive disruption, or geopolitical events. Macro and qualitative risks remain material and should be assessed independently.
No. This overview dashboard aggregates data from our DCF intrinsic value model, relative peer multiples model, proprietary estimates engine, and third-party analyst consensus feeds. It is strictly for educational and informational purposes. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, quality scores, and signals are automated quantitative computations and should not be construed as investment recommendations. Consult a qualified, licensed financial advisor before making any investment decisions. Past model performance does not guarantee future results.